Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.
Dardiotis E, Perpati G, Borsos M, Nikolaidis I, Tzanetakos D, Deretzi G, Koutlas E, Kilidireas C, Mitsikostas DD, Hadjigeorgiou G, Grigoriadis N; AURELIO investigators. Dardiotis E, et al. Among authors: kilidireas c. Neurol Ther. 2022 Sep;11(3):1375-1390. doi: 10.1007/s40120-022-00384-2. Epub 2022 Jul 13. Neurol Ther. 2022. PMID: 35829919 Free PMC article.
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Kilidireas C, Voumvourakis K. Tsivgoulis G, et al. Among authors: kilidireas c. PLoS One. 2015 Mar 10;10(3):e0116511. doi: 10.1371/journal.pone.0116511. eCollection 2015. PLoS One. 2015. PMID: 25756363 Free PMC article. Review.
The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, Dardiotis E, Kilidireas C, Voumvourakis K; HELANI (Hellenic Academy of Neuroimmunology). Tsivgoulis G, et al. Among authors: kilidireas c. Ther Adv Neurol Disord. 2015 Sep;8(5):193-202. doi: 10.1177/1756285615600381. Ther Adv Neurol Disord. 2015. PMID: 26557896 Free PMC article.
The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, Kilidireas C, Voumvourakis K, Dardiotis E; HELANI (Hellenic Academy of Neuroimmunology). Tsivgoulis G, et al. Among authors: kilidireas c. PLoS One. 2015 Dec 7;10(12):e0144538. doi: 10.1371/journal.pone.0144538. eCollection 2015. PLoS One. 2015. PMID: 26642051 Free PMC article. Review.
The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
Tsivgoulis G, Katsanos AH, Mavridis D, Grigoriadis N, Dardiotis E, Heliopoulos I, Papathanasopoulos P, Karapanayiotides T, Kilidireas C, Hadjigeorgiou GM, Voumvourakis K; HELANI (Hellenic Academy of Neuroimmunology). Tsivgoulis G, et al. Among authors: kilidireas c. PLoS One. 2016 Sep 29;11(9):e0163296. doi: 10.1371/journal.pone.0163296. eCollection 2016. PLoS One. 2016. PMID: 27684943 Free PMC article.
Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis.
Tsivgoulis G, Katsanos AH, Voumvourakis K, Hadjigeorgiou GM, Heliopoulos I, Karapanayiotides T, Papathanasopoulos P, Kilidireas C, Grigoriadis N. Tsivgoulis G, et al. Among authors: kilidireas c. Mult Scler Relat Disord. 2018 Apr;21:117-119. doi: 10.1016/j.msard.2018.03.010. Epub 2018 Mar 15. Mult Scler Relat Disord. 2018. PMID: 29724375 No abstract available.
Hippocampal structural and functional integrity in multiple sclerosis patients with or without memory impairment: a multimodal neuroimaging study.
Karavasilis E, Christidi F, Velonakis G, Tzanetakos D, Zalonis I, Potagas C, Andreadou E, Efstathopoulos E, Kilidireas C, Kelekis N, Evdokimidis I. Karavasilis E, et al. Among authors: kilidireas c. Brain Imaging Behav. 2019 Aug;13(4):1049-1059. doi: 10.1007/s11682-018-9924-y. Brain Imaging Behav. 2019. PMID: 29971687
X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association.
Koutsis G, Breza M, Velonakis G, Tzartos J, Kasselimis D, Kartanou C, Karavasilis E, Tzanetakos D, Anagnostouli M, Andreadou E, Evangelopoulos ME, Kilidireas C, Potagas C, Panas M, Karadima G. Koutsis G, et al. Among authors: kilidireas c. J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):187-194. doi: 10.1136/jnnp-2018-319014. Epub 2018 Sep 8. J Neurol Neurosurg Psychiatry. 2019. PMID: 30196252
Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".
Tsivgoulis G, Palaiodimou L, Katsanos AH, Voumvourakis K, Hadjigeorgiou GM, Heliopoulos I, Karapanayiotides T, Papathanasopoulos P, Kilidireas C, Grigoriadis N. Tsivgoulis G, et al. Among authors: kilidireas c. CNS Drugs. 2019 Mar;33(3):293-295. doi: 10.1007/s40263-019-00615-5. CNS Drugs. 2019. PMID: 30806966 No abstract available.
Recurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review.
Vakrakou AG, Evangelopoulos ME, Boutzios G, Tzanetakos D, Tzartos J, Velonakis G, Toulas P, Anagnostouli M, Andreadou E, Koutsis G, Stefanis L, Fragoulis GE, Kilidireas C. Vakrakou AG, et al. Among authors: kilidireas c. Rheumatol Int. 2020 Feb;40(2):337-343. doi: 10.1007/s00296-019-04502-6. Epub 2020 Jan 2. Rheumatol Int. 2020. PMID: 31898763 Review.
53 results